Leukemia Drug's clotting risks under microscope in new study
NCT ID NCT07071051
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study looks at how the chemotherapy drug calaspargase pegol changes blood clotting in children with acute lymphoblastic leukemia (ALL). Researchers will take blood samples before and after treatment to track clotting changes and any related side effects. The goal is to better understand these risks so doctors can manage them more safely. About 15 children aged 2 to 21.5 years will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.